Board and executive changes

; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On November 4, 2026, Taha Kass-Hout notified GE HealthCare Technologies Inc. (“GE HealthCare”) that he will resign as Chief Science and Technology Officer. Mr. Kass-Hout’s last day at GE HealthCare will be December 31, 2026.

On November 3, 2026, Pfizer Inc. (the “Company”) announced that the Board of Directors of the Company unanimously elected Cecile Guegan to serve as Chief Financial Officer, Executive Vice President of the Company, effective November 1, 2026 (the “Effective Date”). As reported in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on June 18, 2026, Ms. Guegan, 55, was previously appointed as the Company’s Interim Chief Financial Officer, effective August 16, 2026. Ms. Guegan has more than 25 years of global finance leadership in the pharmaceutical industry. She joined Pfizer in connection with its 2009 acquisition of Wyeth, where she had served as chief financial officer supporting the Asia Pacific and EMEA/Canada businesses.

Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers On October 28, 2026, Jennifer L. Davis, a Class II director of AbbVie Inc. (“AbbVie”), notified the Company’s Board of Directors (the “Board”), of her intent to resign from the Board, effective November 2, 2026, in light of her recent appointment as Chief Executive Officer at Align Technology, Inc. Her resignation as a director is not the result of any dispute or disagreement with AbbVie on any matter relating to the operations, policies or practices of AbbVie.

On October 29, 2026, the Board of Directors (the “Board”) of Intuitive Surgical, Inc. (the “Company”) approved an increase in the size of the Board from ten to eleven members and appointed Aaron Martin to fill the resulting vacancy, effective as of January 1, 2027. Mr. Martin will not be appointed to any committees as of the effective date. The Board has determined that Mr. Martin is an independent director under applicable rules of the Nasdaq Stock Market (“Nasdaq”) and the U.S. Securities and Exchange Commission. Pursuant to the Company’s standard compensation program for its non-employee directors, Mr. Martin will receive an annual cash retainer of $70,000 for service as a member of the Board, which amount will be prorated for the portion of the fiscal year remaining following the effective date of his appointment. Mr.

On October 27, 2026, Thermo Fisher Scientific Inc. (the “Company”), announced that Michael D. Shafer, Executive Vice President of the Company, will retire effective December 31, 2026. 2

On October 22, 2026, Jeannette Bankes notified GE HealthCare that she will resign as President and CEO, Patient Care Solutions. Ms. Bankes' last day at GE HealthCare will be November 15, 2026.

CEO Succession and Appointment of New Director On October 26, 2026, the Board of Directors (the “ Board ”) of Align Technology, Inc. (the “ Company ”) appointed Jennifer L. Davis as Chief Executive Officer-elect and director of the Company, effective November 2, 2026 (the “ Commencement Date ”), and as President and Chief Executive Officer (“ CEO ”) of the Company, effective December 31, 2026. Joseph M. Hogan will continue to serve as the Company’s President and CEO through December 31, 2026, at which time he will retire and begin serving as a strategic advisor to the Company under the terms of an Executive Consulting Agreement, executed October 27, 2026 (the “ Hogan Consulting Agreement ”). During the transition period from November 2, 2026 through December 31, 2026, Ms. Davis will work with Mr.

Departure of President and Chief Executive Officer On October 27, 2026, Albert G. White III resigned from the Board of Directors (the “Board”) of The Cooper Companies, Inc. (the “Company”) and he ceased serving in the offices of President and Chief Executive Officer of the Company. Mr. White has agreed to remain employed full time as a strategic advisor to the Company through April 1, 2027 to assist in the transition of his responsibilities. Mr. White will receive the payments and benefits to which he is entitled under his Executive Employment Agreement with the Company, dated March 19, 2024, as described under the caption “Quantification of Potential Payments” in the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission (the “SEC”) on February 24, 2026 (the “Proxy Statement”), which description is incorporated herein by reference.

(d) Election of Directors. On October 26, 2026, the Board of Directors (the “Board”) of Amgen Inc. (the “Company”) appointed David W. Gibbs as a director of the Company, effective immediately. Mr. Gibbs served as Chief Executive Officer of Yum! Brands, Inc., a leading global restaurant company, from 2020 to September 2025 and as a director of Yum! Brands from 2019 to September 2025. Since October 2025, Mr. Gibbs has served as an advisor to Yum! Brands. Previously, he served as President and Chief Operating Officer of Yum! Brands from August 2019 to December 2019; President, Chief Operating Officer and Chief Financial Officer from January 2019 to August 2019; and President and Chief Financial Officer from 2016 to 2018. Earlier in his career at Yum! Brands, Mr. Gibbs served as Chief Executive Officer of the Pizza Hut Division from 2015 to 2016, President of Pizza Hut U.S.

(d) On October 20, 2026, Daniel Brennan was appointed as a new member of the board of directors (the “Board”) of Vertex Pharmaceuticals Incorporated (the “Company”). In connection with the appointment of Mr. Brennan, the size of the Board was increased from ten to eleven members. Mr. Brennan also has joined our Audit and Finance Committee. Mr. Brennan served as the Executive Vice President, Chief Financial Officer of Boston Scientific Corporation, a medical device and healthcare technology company, from January 2014 until his retirement in June 2025. He was the Senior Vice President, Corporate Controller from 2010 through 2013 and, prior to that role, he held various roles of increasing responsibility within the finance function from 1996 through 2009. Mr.

On October 15, 2026, the Board of Directors (the "Board") of Medtronic plc (the “Company”) approved the appointment of Michael Marinaro, Executive Vice President and President, Medical Surgical Portfolio, Americas, and Global Commercial Operations to the role of President, Medtronic, effective October 14, 2026. In this expanded role, Mr. Marinaro will continue with his current responsibilities, in addition to exercising oversight responsibility for the Company’s Greater China operations, which will continue to be managed locally by Alex Gu, Senior Vice President and President, Greater China. Mr. Marinaro will continue to report to Geoffrey S. Martha, who will continue to serve as the Company’s Chairman of the Board of Directors and Chief Executive Officer. In connection with Mr.

Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers On October 14, 2026, AbbVie Inc. (“AbbVie”) expanded the size of its Board of Directors (the “Board”) from twelve directors to thirteen directors and appointed Dr. John M. Carethers as a Class II director. Dr. Carethers currently serves as the Vice Chancellor for Health Sciences at the University of California San Diego and was previously a director of Avantor, Inc. Dr. Carethers has been appointed to the Public Policy and Sustainability Committee of AbbVie. The Board affirmatively determined that Dr. Carethers is an “independent director” under each of the standards set forth in section 303A.02 of the New York Stock Exchange Listed Company Manual and AbbVie’s Governance Guidelines and Director Independence Guidelines. Dr.

On October 8, 2026, the Board of Directors (the "Board") of Zoetis Inc. (the “Company”) appointed Iris Knobloch to the Board, effective as of December 1, 2026, to serve in such capacity until her successor is appointed or qualified or until her resignation or removal. In connection with the appointment of Ms. Knobloch, the size of the Board will be increased from twelve to thirteen members effective as of December 1, 2026. Ms. Knobloch has been appointed to serve on the Board’s Corporate Governance Committee. Ms. Knobloch was not appointed to the Board pursuant to any arrangements or understandings with any third party, and since the beginning of the last fiscal year, there have been no related party transactions between the Company and Ms. Knobloch that would be reportable under Item 404(a) of Regulation S-K.

Director Appointments On October 9, 2026, the Board of Directors (the “Board”) of Danaher Corporation (the “Company” or “Danaher”) increased the size of the Board to thirteen members and appointed Daniel L. Comas and Robert M. Hershberg to the Board, in each case effective immediately. Each of Mr. Comas and Dr. Hershberg will serve until the Company’s next annual meeting of shareholders and until his successor is duly elected and qualified, or until his earlier death, resignation or removal. Dr. Hershberg has also been appointed to serve as a member of the Science and Technology Committee of the Board. Daniel L. Comas, age 62, joined the Company in 1991 and served as Executive Vice President from April 2005 through December 2020, including as Chief Financial Officer from April 2005 through December 2018. During his tenure, Mr.

(d) Incorporated by reference is a press release issued by Merck & Co., Inc. (the “Company”) on October 13, 2026, attached as Exhibit 99.1, announcing the election of Paul J. Diaz to the Company’s Board of Directors (the “Board”), effective November 1, 2026. The Board appointed Mr. Diaz as a member of both the Audit Committee and the Research Committee of the Board. For his service on the Board, Mr. Diaz will receive compensation as a non-employee director in accordance with the Company’s non-employee director compensation practices described under the “Director Compensation” section of the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 8, 2026. Mr.

On October 6, 2026, Donna F. Zarcone informed the Board of Directors (the “Board”) of The Cigna Group (the “Company”) that she will retire from the Board effective December 31, 2026. Ms. Zarcone’s retirement is not the result of any disagreement with the Company.

On October 8, 2026, Henry Schein, Inc. (the “Company”) announced that (i) Ronald N. South will continue to serve as Senior Vice President and Chief Financial Officer of the Company and as the Company’s principal financial officer and principal accounting officer through November 3, 2026, including through the completion of the Company’s third quarter earnings process, and effective November 4, 2026, Mr. South’s employment will transition to the role of Senior Advisor and (ii) the Board of Directors (the “Board”) approved the appointment of Emmanuel Caprais to initially serve as Senior Financial Advisor of the Company on October 12, 2026, allowing for a structured transition and onboarding period, and effective November 4, 2026 to serve as Senior Vice President, Chief Financial Officer of the Company and as the Company’s principal financial officer and principal accounting officer.

Chief Operating Officer On October 7, 2026, Boston Scientific Corporation (the “Company”) announced that Joe Fitzgerald, who currently serves as Executive Vice President and Group President, Cardiovascular, has been promoted to Executive Vice President and Chief Operating Officer of the Company, effective as of January 1, 2027. Mr. Fitzgerald, age 63, joined the Company in 1990, and has held a variety of management positions in the Company’s Cardiovascular business. In his current position, which he has held since May 2022, Mr. Fitzgerald oversees development and commercialization of advanced heart therapies for health care professionals and patients globally. Prior to that, Mr.

Stryker Corporation (the “Company”) announced on October 6, 2026 that Kevin A. Lobo will resign from his role as Chief Executive Officer (“CEO”) of the Company on December 31, 2026 and transition to the role of Executive Chair of the Board of Directors of the Company (the “Board”), effective January 1, 2027 (the “CEO Transition”) and that Spencer S. Stiles, who currently serves as President and Chief Operating Officer of the Company, has been appointed CEO of the Company, effective January 1, 2027. In connection with Mr. Stiles’s appointment as CEO, the Board also increased the size of the Board from 10 to 11 and appointed Mr. Stiles to serve as a member of the Board, effective January 1, 2027. Mr. Stiles has not been appointed to any committee of the Board at this time. There are no arrangements or understandings between Mr. Stiles and any other person pursuant to which Mr.

On October 6, 2026, Quest Diagnostics Incorporated (the “Company”) announced that Catherine T. Doherty will retire in July 2027. Until then, effective November 1, 2026, Ms. Doherty will transition to a new role as Executive Vice President with responsibilities including health systems, the Company’s joint venture with Corewell Health, and Project Nova, the Company’s multi-year project to modernize its “Order to Cash” business processes, which includes the related information technology infrastructure and underlying enabling technologies. In connection with this transition, the Company’s Compensation and Leadership Development Committee (the “Committee”) approved no change to Ms. Doherty’s annual base salary of $650,000 or annual incentive compensation under the Company's Senior Management Incentive Plan with a target amount of 80% of base salary.

(b) and (c) On September 30, 2026, Moderna, Inc. (“Moderna” or the “Company”) announced the appointment of Juan Andres as its Chief Operating Officer (“COO”) effective October 5, 2026. In this newly created role, Mr. Andres will support the increasing scale and diversification of the Company and will report to Chief Executive Officer Stephane Bancel and serve on the Company’s Executive Committee. Mr. Andres, 62, previously spent nearly six years at Moderna, including serving as its Chief Technical Operations and Quality Officer from 2018 through 2022 and as its President, Strategic Partnerships and Enterprise Expansion before retiring from Moderna in 2023.

1.     New Equity Awards for CEO and CSO Effective September 24, 2026 (the “ Grant Date ”), the Compensation Committee (the “ Compensation Committee ”) of the Board of Directors (the “ Board ”) of Regeneron Pharmaceuticals, Inc. (“ Regeneron ” or the “ Company ”) granted, upon the approval of the independent, non-employee members of the Board, a one-time award of performance share units (together, the “ 2026 PSUs ”) under the Second Amended and Restated Regeneron Pharmaceuticals, Inc. 2014 Long-Term Incentive Plan (the “ Equity Plan ”) to each of Leonard S. Schleifer, M.D., Ph.D., Board co-Chair, President and Chief Executive Officer of the Company (“ CEO ”), and George D. Yancopoulos, M.D., Ph.D., Board co-Chair, President and Chief Scientific Officer of the Company (“ CSO ”), as described below.

Director Appointment On September 24, 2026, the Board of Directors (the “Board”) of Cencora, Inc. (the “Company”) appointed Robert E. Sanchez to serve on the Board (the “Appointment”), effective October 1, 2026 (the “Effective Date”). In connection with the Appointment, the Board increased from ten to eleven members in accordance with the Company’s Amended and Restated Bylaws. Mr. Sanchez will receive the same benefits and compensation as the other non-employee directors on the Board pursuant to the Company’s Compensation Policy for Non-Employee Directors, as described on pages 40 to 41 of the Definitive Proxy Statement on Schedule 14A filed by the Company with the Securities and Exchange Commission on January 22, 2026.

On September 21, 2026, Arthur C. Butcher informed Boston Scientific Corporation (the “Company”) that he has decided to retire from his role as Executive Vice President and Group President, MedSurg and Asia Pacific effective as of January 1, 2027. Mr. Butcher is expected to remain with the Company as a senior advisor from such time through February 26, 2027 (such date, or any earlier date, the “Retirement Date”). As a senior advisor, Mr. Butcher will receive a base salary at his current annual base salary of $780,000, prorated through the Retirement Date. The Company expects to enter into a Retirement Agreement with Mr. Butcher effective as of the Retirement Date, pursuant to which Mr. Butcher will be entitled to payments and benefits that are materially consistent with those Mr.

On September 22, 2026, the Board of Directors (the “Board”) of GE HealthCare Technologies Inc. (the “Company”) appointed Pascal Desroches to serve as a director of the Company, effective January 4, 2027. The Board also appointed Mr. Desroches as a member of the Audit Committee and the Talent, Culture, and Compensation Committee of the Board, effective January 4, 2027. Upon joining the Board, Mr. Desroches will receive compensation in accordance with the Company’s compensation program for non-employee directors, which is described in the Company’s Definitive Proxy Statement on Schedule 14A filed with the U.S. Securities and Exchange Commission (the “SEC”) on March 19, 2026. The Company will also enter into an indemnification agreement with Mr. Desroches.

Adoption of Nonqualified Deferred Compensation Plan On September 14, 2026, the Talent and Compensation Committee (the "Committee") of the Board of Directors (the "Board") of Insulet Corporation (the "Company") approved and adopted the Insulet Nonqualified Deferred Compensation Plan (the "Plan"), with such Plan to be effective on January 1, 2027. The Plan is intended to be an unfunded "top hat" deferred compensation plan that allows a select group of management or highly compensated employees within the meaning of the Employee Retirement Income Security Act of 1974, as amended ("ERISA"), including the Company’s named executive officers, to voluntarily defer compensation in a manner intended to comply with Section 409A of the Internal Revenue Code of 1986, as amended (the "Code").

On September 10, 2026, the Board of Directors (the “Board”) of DexCom, Inc. (“Dexcom” or the “Company”) appointed Jereme Sylvain, the Company’s EVP, Chief Financial Officer, to the role of EVP, Chief Operating Officer and Chief Financial Officer, effective September 14, 2026. In connection with Mr. Sylvain’s promotion, on September 11, 2026, Mr. Sylvain entered into an offer letter with the Company (the “Offer Letter”) providing for an annual base salary of $767,000 and annual target bonus opportunity equal to 75% of his base salary. Mr. Sylvain remains eligible to receive annual equity awards under the Company’s Amended and Restated 2015 Equity Incentive Plan, to participate in the Company’s Amended and Restated Severance & Change in Control Plan as an executive officer, and to participate in the employee benefit plans that Dexcom offers to its other employees.

On September 3, 2026, Timothy J. Scannell, a member of the Board of Directors (the "Board") of Insulet Corporation (the "Company"), notified the Company of his decision to step down from the Board for health reasons, effective September 3, 2026. The Board and management extend their sincere appreciation to Mr. Scannell for his leadership, unwavering commitment and invaluable guidance to the Company throughout his 12 years of service on the Board, including 7 years as Chairman of the Board, during which he helped guide the Company through a period of significant growth and advancement. On September 8, 2026, Michael R. Minogue also notified the Company of his decision to step down from the Board to focus on his candidacy for Governor of Massachusetts, effective September 15, 2026. The Board and management are grateful to Mr.

On September 10, 2026, the Board of Directors (the “Board”) of DexCom, Inc. (“Dexcom” or the “Company”), pursuant to the Amended and Restated Bylaws of the Company, increased the size of the Board to thirteen directors and appointed Glenn S. Boehnlein as a director, effective immediately. Mr. Boehnlein will hold office for a term expiring at the 2027 annual meeting of Dexcom’s stockholders (the “2027 Annual Meeting”). The Board also appointed Mr. Boehnlein to serve as a member of the Operations & Innovation Committee and the Audit Committee of the Board, effective immediately. There is no arrangement or understanding between Mr. Boehnlein and any other persons pursuant to which Mr. Boehnlein was selected as a director. Mr.

On September 8, 2026, Zimmer Biomet Holdings, Inc. (the “Company”) notified Kevin Thornal, Group President, Global Businesses and the Americas, that his position is being restructured. Mr. Thornal will be departing from the Company, effective on September 30, 2026. Mr. Thornal will be eligible for severance benefits under the Company’s Restated Executive Severance Plan, as amended (the “Severance Plan”). Pursuant to the Severance Plan, Mr. Thornal will receive benefits, including a lump sum amount equal to the sum of twelve months of his annual base salary plus target annual bonus, plus twelve months of his current monthly COBRA premiums. His right to receive such severance payments and benefits is conditioned upon his executing and not revoking a general release in favor of the Company.

(b) On September 2, 2026, Boon Hwee Koh, Chairperson of the Board of Directors (the "Board") of Agilent Technologies, Inc. (the "Company"), notified the Company of his decision to retire from the Board, effective as of September 4, 2026. Mr. Koh's decision to retire was not due to any disagreement with the Company or the Board on any matter relating to the Company's operations, policies or practices. The Company and the Board thank Mr. Koh for his valuable insights, perspective, and commitment during his 23-year service on the Board. (d) On September 4, 2026, the Board upon the recommendation of its Nominating/Corporate Governance Committee, appointed Glenn Boehnlein, to fill the vacancy created by the resignation of Mr. Koh, effective September 4, 2026 to serve as a Class III director, the class of directors that will stand for re-election at the 2027 Annual Meeting of Stockholders.

On August 27, 2026, Vertex Pharmaceuticals Incorporated (the “Company”) appointed Jonathan Poole as Executive Vice President and Chief Financial Officer of the Company, effective January 1, 2027 (the “Effective Date”). In connection with Mr. Poole’s appointment, Charles F. Wagner, Jr., the Company’s Executive Vice President and Chief Operating & Financial Officer, will cease serving as Chief Financial Officer as of the Effective Date, but will remain Executive Vice President and Chief Operating Officer. Mr. Poole, 51, has been Senior Vice President, Finance at the Company since March 2020. Previously, Mr. Poole served as Chief Financial Officer of Evelo Biosciences, Inc. from March 2018 to March 2020 and as Chief Financial Officer of Genocea Biosciences, Inc. from April 2014 to March 2018. Earlier in his career, Mr.

Appointment of Quentin Blackford On August 27, 2026, the Board of Directors (the “Board”) of Align Technology, Inc. (the “Company”) appointed Quentin Blackford, 48, to the Board. In connection with Mr. Blackford’s appointment, the Board increased the size of the Board from ten to eleven directors. The Company expects Mr. Blackford to stand for election at the next annual meeting of stockholders, which is expected to be held in May 2027. Mr.

The Board of Directors of Edwards Lifesciences Corporation, a Delaware corporation (“Edwards” or the “Company”), has received notice from Donald E. Bobo, Jr., Corporate Vice President, Strategy and Corporate Development, of his decision to retire from the Company by mid-year 2027. A selection process will begin promptly to identify a successor, which is expected to result in a transition of duties during 2027. Mr. Bobo is also expected to remain as a consultant with the Company through the end of 2027. 2

(b) On August 17, 2026, Robert L. Carpio III notified Waters Corporation (the “Company”) of his decision to resign from his position as Senior Vice President, Waters Analytical Sciences Division to pursue other opportunities. Mr. Carpio relinquished his duties related to such position effective August 20, 2026.

On August 20, 2026, Veeva Systems Inc. (“Veeva”) announced the appointment of Dan Rizzo to serve as EVP, Sales, Consulting, and Services, effective October 2, 2026. Mr. Rizzo succeeds Thomas D. Schwenger, who has been with Veeva since September 2019, most recently serving as President and Chief Customer Officer. Mr. Schwenger informed Veeva of his decision to resign on August 18, 2026 and his resignation is effective October 2, 2026. Mr. Schwenger is departing to assume a CEO role at a long-standing Veeva partner. Veeva thanks Mr. Schwenger for his outstanding service to Veeva and its customers for the past seven years.

Appointment of John Rogers as CFO On August 18, 2026, Baxter International Inc. (the “Company”) appointed John Rogers as Executive Vice President and Chief Financial Officer (“CFO”), effective as of October 1, 2026 (the “Transition Date”). Mr. Rogers, 58, is joining the Company from Smith+Nephew plc, where he has served as CFO since 2024 after beginning with the company as CFO-designate in 2023. Before Smith+Nephew, he served as CFO of WPP plc from 2020 to 2023. Rogers previously held leadership roles with J Sainsbury plc, including as CEO of Sainsbury’s Argos from 2016 to 2019 and as CFO of Sainsbury’s from 2010 to 2016. Mr. Rogers has also served as an independent director and audit committee chair of Grab Holdings Limited since 2021 and of Travis Perkins plc between 2014 and 2021. Mr.

On August 13, 2026, the Board of Directors (the “Board”) of GE HealthCare Technologies Inc. (“GE HealthCare”) appointed William K. Grogan as Chief Financial Officer, effective September 14, 2026. George A. Newcomb, who currently serves as GE HealthCare’s interim Chief Financial Officer, will cease serving in that interim role on September 14, 2026, and will continue serving as GE HealthCare’s Controller and Chief Accounting Officer. Mr. Grogan, age 48, has served as Executive Vice President and Chief Financial Officer of Xylem Inc., a global water solutions company, since October 2023. Previously, Mr. Grogan served as Senior Vice President and Chief Financial Officer of IDEX Corporation, a global engineered products company, from January 2017 until September 2023. On August 13, 2026, the Talent, Culture, and Compensation Committee (the “Committee”) of the Board approved Mr.

On August 13, 2026, Ronald Taylor, a director of Resmed, informed the Board that he will not stand for election at Resmed’s 2026 annual meeting of stockholders (the “Annual Meeting”) and intends to retire from the Board, effective at the Annual Meeting, which is expected to be held on November 18, 2026. Mr. Taylor’s intention to retire is not due to any disagreement with Resmed on any matter relating to Resmed’s operations, policies or practices. In connection with Mr. Taylor’s retirement, the Board approved the appointment of Carol Burt as lead director, effective November 15, 2026.

On August 13, 2026, Larry M. Robbins notified the Board of Directors (the “Board”) of CVS Health Corporation (the “Company”) of his resignation from the Board, effective immediately. Mr. Robbins’ resignation was not the result of any disagreement with the Company on any matter relating to the operations, policies or practices of the Company. On August 17, 2026, the Board appointed Teresa Heitsenrether to the Board, effective November 18, 2026. Ms. Heitsenrether, age 61, is Executive Vice President and Chief Data & Analytics Officer of JPMorgan Chase & Co. (“JPMorgan Chase”) and is a member of JPMorgan’s Operating Committee. Prior to her current role, Ms. Heitsenrether held several senior leadership positions at JPMorgan Chase, including CEO of Securities Services and Global Head of Prime Brokerage & Equity Financing. She holds an M.B.A. from New York University and a B.S.

On August 12, 2026, Andrew Asher, Chief Financial Officer of Centene Corporation (the Company), informed the Company that he intends to retire as Chief Financial Officer effective as of December 31, 2026. Thereafter, Mr. Asher will serve as Strategic Advisor, reporting to Sarah M. London, the Company’s Chief Executive Officer, through the end of 2027, to ensure an orderly transition and to support certain strategic initiatives of the Company. On August 17, 2026, the Company announced that it has identified Christopher Neczypor as Mr. Asher’s successor to be Chief Financial Officer of the Company, with such appointment intended to be effective as of January 1, 2027. Mr.

On August 13, 2026, following the conclusion of the quarterly meeting of the Board of Directors (the “Board”) of Cencora, Inc. (the “Company”), Lorence H. Kim, M.D., informed the Company of his intent to resign from the Board effective immediately. Dr. Kim’s decision was made in connection with his appointment as Chief Financial Officer of Commonwealth Fusion Systems, Inc. and his need to devote additional time to his professional responsibilities at that company. Dr. Kim has advised the Company that his resignation is not due to any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. The Company thanks Dr. Kim for his dedicated service.

On August 11, 2026, Megan D. Bailey notified Labcorp Holdings Inc. (the “Company”) of her decision to resign as Executive Vice President and President, Central Laboratories and International of the Company, effective September 4, 2026. Effective September 1, 2026, Brian J. Caveney, M.D., the current Executive Vice President and President, Early Development Research Laboratories and Chief Medical and Scientific Officer of the Company, will assume the role of Executive Vice President and President, Biopharma Laboratory Services and Chief Medical and Scientific Officer, with responsibility for the Company's Early Development Research Laboratories and Central Laboratories businesses.